Immunic Reviews 2025 Progress and Sets Sights on Future Goals

Immunic, a biotechnology firm, reported significant 2025 achievements, notably in their phase 3 ENSURE trials for Vidofludimus Calcium in relapsing multiple sclerosis (RMS). Enrollment is complete, with top-line data anticipated by late 2026. Phase 2 CALLIPER data underscored the drug's potential in progressive multiple sclerosis (PMS), indicating reduced disability worsening.

Additionally, long-term data from the phase 2 EMPhASIS trial revealed favorable safety and effectiveness in relapsing-remitting multiple sclerosis (RRMS). A recent U.S. patent secures intellectual property until 2041, enhancing product protection. IMU-856 is also progressing, showing promise in gastrointestinal disorders.

Key corporate developments include substantial fundraising efforts, demonstrating strong investor confidence. Immunic will participate in the upcoming J.P. Morgan Healthcare Conference to further engage with investors and stakeholders.